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Summary
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has
been significantly improved by intensified first-line regimens containing
cytarabine, rituximab and consolidation with high-dose-therapy and autol-
ogous stem cell transplantation. One such strategy is the Nordic MCL2 reg-
imen, developed by the Nordic Lymphoma Group. We here present the
15-year updated results of the Nordic MCL2 study after a median follow-
up of 114 years: For all patients on an intent-to-treat basis, the median
overall and progression-free survival was 127 and 85 years, respectively.
The MCL International Prognostic Index (MIPI), biological MIPI, includ-
ing Ki67 expression (MIPI-B) and the MIPI-B including mIR-18b expres-
sion (MIPI-B-miR), in particular, significantly divided patients into distinct
risk groups. Despite very long response durations of the low and interme-
diate risk groups, we observed a continuous pattern of relapse and the sur-
vival curves never reached a plateau. In conclusion, despite half of the
patients being still alive and 40% in first remission after more than
12 years, we still see an excess disease-related mortality, even among
patients experiencing long remissions. Even though we consider the Nordic
regimen as a very good choice of regimen, we recommend inclusion in
prospective studies to explore the benefit of novel agents in the frontline
treatment of MCL.
Keywords: Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, clinical tri-
als, high dose therapy.
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Traditionally, Mantle Cell Lymphoma (MCL) has been asso-
ciated with a poor prognosis with a median overall survival
of 3–5 years (Herrmann et al, 2009; Abrahamsson et al,
2014). However, during the last 10–15 years the treatment of
MCL patients, especially younger cases, has been improved
substantially by two developments: (i) intensified induction
immunochemotherapy including cytarabine (Ara-C) and
anti-CD20 antibodies, and (ii) consolidating high-dose ther-
apy with autologous stem cell transplantation (ASCT) (Drey-
ling et al, 2005; Romaguera, 2005; Geisler et al, 2008;
Hermine et al, 2012; Delarue et al, 2013). The value of ASCT
has not yet been rigorously tested in the setting of intensive
immunochemotherapy induction. Accordingly, the Nordic
MCL2 trial reached a median 6-year progression-free survival
(PFS) and overall survival (OS) of 66% and 70%, respectively
(Geisler et al, 2008), and the updated version reported pro-
jected a 10-year PFS and OS of 43% and 58%, respectively
(Geisler et al, 2012).
Mantle Cell Lymphoma remains a heterogeneous disease,
necessitating prognostic models. The Mantle Cell Lymphoma
International Prognostic Index (MIPI) and MIPI-B (biologi-
cal MIPI including the Ki67 index), remain valid prognosti-
cators also when tested in trials with long follow-up
(Romaguera et al, 2010; Geisler et al, 2012; Hoster et al,
2014).
However, the search continues for new biomarkers to
improve the risk stratification of patients, particularly those
that can aid identification of patients with very aggressive
disease. Such patients do not show satisfactory responses to
standard therapy and therefore could benefit from alterna-
tive, novel treatment modalities (Oberley et al, 2013; Delfau-
Larue et al, 2015; Husby et al, 2015).
In recent years, several novel biologically targeted agents
have been introduced in MCL, mainly registered for use in
the relapse setting (Wang et al, 2013; Robak et al, 2015;
Ruan et al, 2015). Although these are in the process of
moving up to frontline use, either alone or in combination
with other therapy, the standard first line treatment of
younger patients has remained largely unchanged since the
introduction of the intensified protocols, such as the Nor-
dic regimen (Geisler et al, 2008). Hence, we consider that
this long-term update is still of clinical relevance for the
continued follow-up and salvage treatment of these
patients.
Here we present the updated results of the MCL2 trial,
now reaching a median follow-up time of 114 years, with
focus on relapse, survival and risk groups defined by MCL
prognosticators. In the previous update of this cohort, with a
median follow-up of 65 years, the median OS exceeded
10 years (Geisler et al, 2012). Now we show that relapses
continue to occur even after 5 years, suggesting that the dis-
ease will not be eradicated by strategies that are considered
standard for first line treatment of MCL today.
Material and methods
Patients
From 2000 to 2006 the Nordic Lymphoma Group (NLG)
conducted a phase 2 trial, MCL2, for the initial treatment of
MCL patients aged less than 66 years. Briefly, patients were
newly diagnosed with stage II-IV MCL, all expressing cyclin-
D1 (CCND1) or positive for t(11;14) according to the World
Health Organization criteria for MCL (Swerdlow et al, 2008),
and were untreated at inclusion in the trial. All samples
underwent central pathology review. The MCL2 protocol was
approved by the national medicine agencies and science
ethics committees in Denmark, Norway, Sweden and Fin-
land. Informed consent was obtained from all patients.
Patient characteristics are shown in Table I.
Treatment
The treatment regimen has been described previously (Geisler
et al, 2008). The patients received alternating courses of
maxi-CHOP (cyclophosphamide, doxorubicin, vincristine
and prednisolone) and high-dose Ara-C, 3 of each. Ritux-
imab was co-administered on day 1 in cycles 4 and 5, and
on days 1 and 9 in cycle 6. After an amendment in 2003,
rituximab was administered also in cycles 2 and 3. A stem
cell harvest was performed after cycle 6. Either BEAM (car-
mustine, etoposide, Ara-C, melphalan) or BEAC (carmustine,
etoposide, Ara-C, cyclophosphamide) was used as a high-
dose regimen before ASCT. During the first 5 years of
follow-up, minimal residual disease (MRD) was assessed by
polymerase chain reaction (PCR) for either the clonal IGH
rearrangement or translocation t(11;14). Patients still in
clinical complete remission (CR), who converted from
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PCR-negative to PCR-positive bone marrow or blood, were
offered pre-emptive therapy with rituximab 375 mg/m2
weekly for 4 weeks, to prevent clinical relapse.
Statistics
The statistical assessments and endpoints were performed
according to the National Cancer Institute guidelines (Che-
son et al, 2007). Overall survival (OS), progression-free sur-
vival (PFS) and cumulative incidence of relapse (CIR) were
based on an intent-to-treat principle and measured from the
first day of induction therapy. Subanalyses were used to
stratify patients based on response to induction regimen. As
for OS, the endpoint was death from any cause, whereas for
PFS it was lymphoma relapse/progression or death from any
cause. The endpoint of CIR was MCL-progression or relapse.
Survival curves were made according to the Kaplan–Meier
method, and comparisons were made by log rank tests.
Patients who were lost to follow-up were censored from the
date and status when last known to be alive.
Mantle Cell Lymphoma International Prognostic Index
and MIPI-B were assessed according to Hoster et al (2014),
while the MIPI-B including mIR-18b expression (MIPI-B-
miR) was assessed according to Husby et al (2015).
A multivariate Cox regression analysis was performed to
assess the effect on the outcome of pretreatment prognostic
factors (age, sex, Ki-67 expression, cytological variant and
MIPI) as well as of the response to induction treatment, in
terms of OS and PFS.
Moreover, we estimated expected survival in individuals
comparable to the MCL patients (with respect to age, calen-
dar year of follow-up, sex and country of origin) using data
from the Human Mortality Database (http://www.mortal-
ity.org). The expected survival aims to mimic the survival of
the MCL patients, had they not acquired MCL. An observed
difference between the OS of the patients and the expected
survival in the general population is indicative of excess
mortality (directly or indirectly) attributable to MCL among
the patients. To investigate long-term excess mortality we
re-estimated the expected survival and OS of the patients in
the subsets of patients who were alive and progression-free at
1, 5 and 10 years, respectively. Poisson regression was used
to test if the observed excess mortality rate was significantly
different from zero.
A P-value <005 was considered statistically significant.
Results
Characteristics of the 160 patients included in the study are
presented in Table I. Since the last update (Geisler et al,
2012), one patient was excluded due to change of diagnosis.
After adjusting for this, the overall response rate (ORR) after
the induction treatment was 96% (54% in CR/unconfirmed
CR [CRu]). One hundred and forty-five (91%) patients pro-
ceeded to ASCT and hereof, 130 (897%) achieved a CR or
CRu post-ASCT.
Overall and progression-free survival
With a median follow-up time of 114 years (range 49–
147), the median OS and PFS for all 159 patients were 127
and 85 years, respectively (Fig 1A, B, Table II). Of the 145
patients who proceeded to ASCT, the median OS was not
reached and median PFS was 110 years (Table II). Stratified
by pre-ASCT response, patients who had achieved a CR/CRu
upon induction therapy demonstrated significantly better OS
and PFS than patients in partial remission (P = 00038 for
OS, P < 00001 for PFS) (Figure S1A, B). Five patients
achieved CR after induction treatment, but did not proceed
to ASCT (2 due to harvest failure, 1 due to heart failure, 2
for unknown reasons). Of these, all five relapsed quickly with
a median PFS of 22 years (range 044–50 years).
Late relapses
All survival curves showed late events and convincing pla-
teaus were not observed. Half of all patients had either pro-
gressed or relapsed at 120 years (Fig 1C), and we observed a
continuous pattern of relapse throughout the follow-up,
including relapses later than year 10 (Fig 1C). Of 93 patients
still in first CR at 5 years, 18 relapsed later and, to date, 6
patients have relapsed beyond 10 years. Interestingly, of these
Table I. Characteristics of the 159 patients with mantle cell
lymphoma.
Patient-specific variables n (%)
Male gender 113 (71)
Age (years): median 56
Range 32–65
Stage IV 136 (85)
Splenomegaly 72 (45)
Extranodal disease other than bone marrow 50 (31)
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17 late relapses, only 2 were MIPI high-risk patients, and no
high-risk patients relapsed beyond 8 years (Fig 2B, Figure S2).
Nine relapsing patients, of whom 5 patients are still alive,
have undergone allogeneic stem cell transplantation during
follow-up.
Prognostic factors
Both MIPI (available for 157 Patients) and MIPI-B (available
for 119 patients) significantly separated patients into risk
groups with regards to OS and PFS (Fig 2A–D, Table II). In
general, we observed a continuous occurrence of relapses in
all risk groups (Figure S2). From a recent publication on the
same cohort we had available miR-18b expression on 62
patients (Husby et al, 2015) (Fig 2E, F and Figure S2). The
MIPI-B-miR also separated the OS and PFS curves signifi-
cantly (P < 00001 for all three endpoints), and furthermore
defined a high-risk group with inferior outcome as well as a
low-risk group with superior outcome compared to the
respective groups defined by MIPI and MIPI-B (Table II).
In univariate analyses, Blastoid/pleomorphic cytology
showed a trend towards inferior OS (P = 0096), but no
influence on PFS (P = 038) (Figure S3A, B). In multivariate
analyses (n = 119) MIPI showed significant prognostic
impact on both OS and PFS (P < 00001 and P = 00001,
respectively), whereas the cytological variant (blastoid or
pleomorphic) had borderline negative influence on OS
(P = 00945), but not PFS.
Excess mortality
The overall survival of the MCL patients was significantly
lower (P < 0001) when compared to the expected survival
in the general population (Fig 3A). A similar pattern was
Fig 1. Updated follow-up for the Nordic MCL2 trial for (A) Overall survival (OS), (B) progression-free survival (PFS) and (C) cumulative inci-
dence of relapse (CIR) after an intent-to-treat principle.
Table II. OS and PFS for patients enrolled in the Nordic MCL2 trial.
All intent-to-treat All completed ASCT
n OS PFS n OS PFS
(%) (years) (years) (%) (years) (years)
All 159 127 85 145 NR 110
MIPI 157 127 85 143 NR 110
P <00001 <00001 <00001 00001
low 79 (50) NR 127 73 (51) NR 131
intermediate 41 (26) 110 80 39 (27) 110 82
high 37 (24) 40 25 31 (22) 53 27
MIPI-B 118 124 81 109 127 100
P <00001 00009 00008 00083
low 25 (21) NR 127 24 (22) NR 127
intermediate 38 (32) NR 118 36 (33) NR 119
high 55 (47) 52 27 49 (45) 83 46
MIPI-B-miR 61 124 65 55 124 85
P <00001 <00001 <00001 <00001
low 30 (49) NR 131 29 (53) NR 131
intermediate 21 (34) 83 46 19 (35) 84 46
high 10 (16) 16 10 7 (13) 21 14
ASCT, autologous stem cell transplantation; OS, overall survival; PFS, progression-free survival. All presented as median values. MIPI, Mantle Cell
Lymphoma International Prognostic Index; MIPI-B, biological MIPI including Ki-67 expression; MIPI-B-miR, MIPI algorithm including miR-18b
expression.
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also observed when further stratifying the patients by MIPI,
MIPI-B and MIPI-B-miR (data not shown). When compar-
ing the survival of patients still in first CR after 1, 5 and
10 years to the expected survival in a comparable group from
the general population there was still evidence of excess mor-
tality, although a smaller difference was found with longer
time in first CR (Fig 3B–D). In the 59 patients in remission
after 10 years, only 4 deaths were reported and no deaths
were MCL related; however, 6 MCL relapses occurred.
Late toxicities
Since the last update in 2010 (Geisler et al, 2012), 11 new




Fig 2. Stratification of overall and progression-free survival for MCL2 cohort according to the mantle cell lymphoma prognostic indexes. (A, B)
Mantle Cell Lymphoma International Prognostic Index (MIPI), (C, D) biological MIPI including Ki-67 expression (MIPI-B) and (E, F) MIPI
algorithm including miR-18b expression (MIPI-B-miR).
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non-melanoma skin cancers), thus reaching a total of 20,
including 15 solid tumours (94%) (nasopharyngeal: 1, lung:
1, breast: 2, oesophagus: 1, stomach: 1, bile duct: 1, colon: 2,
kidney: 1 prostate: 4, ovarian: 1). Five myeloid malignancies
(31%) (3 myelodysplastic syndrome [MDS] and 2 acute
myeloid leukaemia [AML]) have been reported and 4 of
these had received additional chemotherapy for MCL relapse
prior to diagnosis of MDS/AML.
Discussion
We present the updated results of the Nordic MCL2 trial
after the longest follow-up to date of a state-of-the-art front-
line treatment regimen of younger MCL patients including
ASCT. Half of the patients are alive more than 12 years after
the end of treatment and 40% are still in their first remis-
sion. However, there is continuous pattern of relapse, and an
excess mortality persists even after long-term remission.
Our results are in agreement with two other multicentre
studies with comparable regimens. Delarue et al (2013) used
CHOP + rituximab (R-CHOP) and R-DHAP (rituximab,
dexamethasone, high-dose Ara-C, cisplatin) followed by
ASCT and produced similar response rates. After a median
follow-up of 56 years the median event-free survival was
69 years and the 5-year survival rate was 75% (comparably,
the 5-year survival rate in our study was 74%). In the Euro-
pean MCL Network trial the median failure-free survival was
73 years for the superior regimen (R-CHOP/R-
DHAP + ASCT) (Hermine et al, 2012), while the median OS
had not been reached after a median follow-up of 43 years.
In 2015, the MD Anderson group (Chihara et al, 2015)
presented updated results for the use of hyper-CVAD/Ara-C/
Methotrexate (MTX) without ASCT; after a median follow-
up of 134 years the median failure-free survival was
65 years and OS was 134 years. These data are thus compa-
rable to ours and confirm the importance of intensive Ara-
C-containing regimens. However, the high response rates
have not been fully reproducible in multicentre studies
(Merli et al, 2012; Bernstein et al, 2013), and compared to
the European approaches, the hyper-CVAD/Ara-C/MTX
approach seems to be a more toxic regimen (Romaguera,
2005; Geisler et al, 2008; Merli et al, 2012; Bernstein et al,
2013; Delarue et al, 2013).
Other induction regimens have been proposed. Both Visco
et al (2013) and Armand et al (2016) presented very high
response rates using a regimen consisting of rituximab,
Fig 3. Conditional survival of the MCL2 patients compared to the estimated survival, had they not acquired MCL (based on data from the
Human Mortality data base; http://www.mortality.org). (A) All patients. Patients in first complete remission after (B) 1 year, (C) 5 years and (D)
10 years, respectively. In (C) and (D) the x-axis has been adjusted to match the curves starting at 5 and 10 years, respectively. MCL, Mantle cell
lymphoma; CR, complete remission; OS, overall survival.
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bendamustine and Ara-C, although these studies only
included a small number of patients.
The contribution of high-dose chemotherapy and ASCT
to an optimal Ara-C containing induction regimen has not
been addressed in controlled trials. The European MCL Net-
work trial compared ASCT to interferon-a maintenance after
CHOP-like induction and demonstrated a prolonged PFS,
however with no significant improvement of the OS (Drey-
ling et al, 2005). The newly launched Triangle trial will inves-
tigate the benefit of ASCT after an optimal rituximab- and
Ara-C-containing induction plus ibrutinib (Dreyling & Fer-
rero, 2016). Until then, ASCT-containing regimens are still
considered standard-of-care for younger patients in Europe
(Robinson et al, 2015).
To thoroughly address the MCL-related survival of the
patients, we matched each patient with controls from the
general population as described in the material and methods
section (Fig 3). As expected, patients displayed an excess
mortality in all prognostic subgroups; however, with appar-
ent decreasing rates after longer time in remission.
The MIPI and MIPI-B still significantly divide patients
into three distinct groups, of which the high-risk groups
show a grave prognosis with refractory disease and early
relapse. The low/intermediate-risk groups demonstrate
impressive response durations, but unfortunately, as we show
here, a continuous occurrence of relapses and, similarly, the
survival curves never reach a plateau (Fig 2A–D and
Figure S2).
This report updates our recent demonstration that
miR-18b expression significantly improves the MIPI-B
prognostication (MIPI-B-miR) (Husby et al, 2015). A highly
significant separation of the curves remains, and the high-
risk patients in particular have an exceedingly poor prognosis
(Fig 2E, F). Ongoing studies in our group are seeking to
unravel the function of miR-18b.
In a large observational study by the NLG including 1389
MCL patients from 2000 to 2011 (including the MCL2
patients) (Abrahamsson et al, 2014), gender was shown to be
an individual prognostic factor in multivariate analyses,
favouring women. This, however, was not the case in this
isolated MCL2 cohort, and only MIPI showed independent
significant impact.
Throughout the follow-up, 5 cases (31%) of secondary
myeloid malignancies were reported. Of these 5 patients only
1 was still in first CR, while the remaining 4 had been
exposed to relapse treatment and thus received a higher
cumulative dose of chemotherapy. Comparably, in the
hyperCVAD/Ara-C/MTX setting, 62% of patients in first CR
experienced a myeloid malignancy after a median follow-up
of 134 years (Chihara et al, 2015). Thus, consolidation with
BEAM/BEAC plus ASCT (as in our trial) does not appear to
increase the risk of secondary myeloid malignancies.
At present, the treatment of MCL is in transition with many
novel targeted agents in development, and the challenge now
seems to be how rather than if they should be incorporated in
the first-line treatment. One such agent is Ibrutinib, which has
produced impressive response rates in the relapse setting
(Wang et al, 2013), and thus has been included in the
European MCL Network’s “Triangle” trial of untreated MCL
patients (EudraCT Number 2014-001363-12) (Dreyling &
Ferrero, 2016). But until convincing data emerge, the
standard-of-care remains an Ara-C containing induction plus
rituximab, followed by high dose chemotherapy and ASCT
(Robinson et al, 2015). More than half of the patients in the
MCL2 trial are still alive after more than 12 years.
In conclusion, despite prolonged remissions, a continuous
pattern of relapses has occurred throughout the follow-up,
and there is an excess mortality among all MCL patients even
after long-term remissions. This underlines the importance
of participating in prospective trials to explore the possible
benefits of novel agents in first line treatment of MCL.
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online version of this article:
Fig S1. Updated follow-up of the Nordic MCL2 trial for
the 145 patients who proceeded to autologous stem cell
transplantation (ASCT), stratified by response (CR/CRu or
PR) pre-ASCT. (A) Overall survival (OS) and (B) progres-
sion-free survival (PFS).
Fig S2. Cumulated incidence of relapse (CIR) of patients
from the Nordic MCL2 trial, stratified by the MCL prognos-
tic indexes (A) MIPI, (B) MIPI-B (C) MIPI-B-miR.
Fig S3. (A) overall and (B) progression-free survival of
patients from the Nordic MCL2 trial according to cytology
in diagnostic samples (Blastoid/pleomorphic “Blastoid” or
non-blastoid/pleomorphic “non-Blastoid”).
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